NFX1 and cervical cancer: When NFX1-123 expression is decreased, pharmacologically or by CRISPR-Cas9 knock out, cervical cancer cell lines have decreased growth, survival, migration, and wound healing, as well as an enhanced cytotoxic efficacy of cisplatin, a widely used chemotherapeutic drug [1].